NT 201 dose-titration study in unilateral upper and lower limb spasticity due to cerebral causes

Phase 3, open-label, single-arm trial of botulinum toxin type A in spastic paresis and spasticity, sponsored by Merz. Primary endpoint: Occurrence of treatment-emergent adverse events, adverse events of special interest, and serious adverse events by injection cycle. Started Oct 2011; status: completed.